Learn about the world’s most advanced ex vivo immuno-oncology models.
GREENVILLE, SC. – February 6, 2019 – KIYATEC, Inc., today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has initiated patient enrollment into KIYATEC’s clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies for solid tumors. In this clinical study, the test analyzes aRead More
3D-PREDICT Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors…Read More
Company’s growth supports upcoming clinical programs to help better predict patient response to oncology drugs before treatment begins…Read More
Innovation milestone is a message of authentic hope for local cancer patients By Matthew Gevaert, Ph.D., and W. Jeffrey Edenfield, MD Cancer innovation and hiking the Appalachian Trail have a few things in common. Neither happens overnight; the AT typically takes five to seven months, and meaningful innovation in cancer research can take five toRead More